Literature DB >> 23515958

Personalised medicine: a critique on the future of health care.

Jacqueline Savard1.   

Abstract

In recent years we have seen the emergence of "personalised medicine." This development can be seen as the logical product of reductionism in medical science in which disease is increasingly understood in molecular terms. Personalised medicine has flourished as a consequence of the application of neoliberal principles to health care, whereby a commercial and social need for personalised medicine has been created. More specifically, personalised medicine benefits from the ongoing commercialisation of the body and of genetic knowledge, the idea that health is defined by genetics, and the emphasis the state places on individual citizens as being "responsible for" their own health. In this paper I critique the emergence of personalised medicine by examining the ways in which it has already impacted upon health and health care delivery.

Mesh:

Year:  2013        PMID: 23515958     DOI: 10.1007/s11673-013-9429-8

Source DB:  PubMed          Journal:  J Bioeth Inq        ISSN: 1176-7529            Impact factor:   1.352


  30 in total

Review 1.  A glossary for evidence based public health.

Authors:  Lucie Rychetnik; Penelope Hawe; Elizabeth Waters; Alexandra Barratt; Michael Frommer
Journal:  J Epidemiol Community Health       Date:  2004-07       Impact factor: 3.710

Review 2.  The marketing of empowerment and the construction of the health consumer: a critique of health promotion.

Authors:  V M Grace
Journal:  Int J Health Serv       Date:  1991       Impact factor: 1.663

3.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

4.  Political power beyond the State: problematics of government. 1992.

Authors:  Nikolas Rose; Peter Miller
Journal:  Br J Sociol       Date:  2010-01

Review 5.  The ethics of expectations: biobanks and the promise of personalised medicine.

Authors:  Alan Petersen
Journal:  Monash Bioeth Rev       Date:  2009-03

6.  Personalized medicine in the era of genomics.

Authors:  Wylie Burke; Bruce M Psaty
Journal:  JAMA       Date:  2007-10-10       Impact factor: 56.272

7.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

8.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

Authors:  R Seshadri; F A Firgaira; D J Horsfall; K McCaul; V Setlur; P Kitchen
Journal:  J Clin Oncol       Date:  1993-10       Impact factor: 44.544

Review 9.  Genomic and personalized medicine: foundations and applications.

Authors:  Geoffrey S Ginsburg; Huntington F Willard
Journal:  Transl Res       Date:  2009-10-01       Impact factor: 7.012

10.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

View more
  4 in total

1.  Risks of nutrigenomics and nutrigenetics? What the scientists say.

Authors:  T Hurlimann; V Menuz; J Graham; J Robitaille; M-C Vohl; B Godard
Journal:  Genes Nutr       Date:  2013-11-29       Impact factor: 5.523

2.  Precision in health care.

Authors:  Henk Ten Have; Bert Gordijn
Journal:  Med Health Care Philos       Date:  2018-12

3.  Precision public health-the Emperor's new clothes.

Authors:  David Taylor-Robinson; Frank Kee
Journal:  Int J Epidemiol       Date:  2019-02-01       Impact factor: 7.196

Review 4.  Ethical implications of epigenetics in the era of personalized medicine.

Authors:  Josep Santaló; María Berdasco
Journal:  Clin Epigenetics       Date:  2022-03-25       Impact factor: 6.551

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.